Quick Take: NeonMind CEO Rob Tessarolo provides an update on the company’s latest R&D initiatives, their 2021 roadmap, and near-future plans on developing synthetic psilocybin-based drug candidates for the treatment of obesity, compulsive eating disorder, and as an aid to weight loss and its maintenance. Over the next six weeks, NeonMind’s R&D group will finalize…